This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Nuvo Pharmaceuticals, Inc.
Drug Names(s): tetrachlorodecaoxide (TCDO), Macrokine, Immunokine, WF-10
Description: WF10 is a 1 : 10 dilution of tetrachlorodecaoxide (TCDO) formulated for intravenous injection. WF10 appears to act on the macrophage (altering functioning and gene activation), a type of white blood cell that coordinates much of the immune system. This may be through the initial reaction of WF10 with hemoproteins and the generation of chloramines, such as taurine chloramine. WF10 may modulate up-regulation of the immune system caused by diseases, by down-regulating inappropriate inflammatory reactions. However, in some cells it also induces pro-inflammatory cytokines. (WF 10 is approved for in Thailand as Immunokine in patients with postradiation chronic inflammatory disease including cystitis, proctitis and mucositis.)
WF10 was originally developed by Oxo Chemie.
Nuvo and Oxo Chemie
In May 2002, Nuvo acquired Oxo Chemie.
Nuvo and Fraunhofer Institute for Cell Therapy
In September 2009, Nuvo announced a cooperative drug development project with the Fraunhofer Institute for Cell Therapy and Immunology IZI and Nuvo subsidiary, Nuvo Research GmbH. The project is for the preclinical and clinical development of WF10 as a potential treatment for allergic rhinitis.
Nuvo and Paladin
In June 2013, Nuvo and Paladin amended their loan arrangement. Paladin will have the right to license the marketing rights to Nuvo's immune modulation drug candidate, WF10, for Canada, South America and Central America (the Paladin Territories). The terms of the license will be the same as commercial terms under any WF10 license from Nuvo to a third party for another territory adjusting any upfront or milestone payments for the proportionate share of total pharmaceutical...See full deal structure in Biomedtracker
Partners: Endo International plc
Pink Sheet Dimethaid WF10 fails Phase III for HIV
Additional information available to subscribers only: